Understanding how cell death influences treatment response in leukemia
Investigating apoptotic priming as a determinant of sensitivity to leukemia-directed therapies
This study is looking at how well leukemia cells can die off naturally and how that affects their response to certain treatments, so we can better understand which patients with acute myeloid leukemia might benefit from new therapies like azacitidine and venetoclax based on their individual cell traits.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10871842 on NIH RePORTER |
What this research studies
This research investigates how the ability of leukemia cells to undergo programmed cell death, known as apoptosis, affects their sensitivity to treatments. By using a technique called BH3 profiling, researchers will analyze patient samples to determine the apoptotic priming of leukemia cells. The study aims to explore how different genetic backgrounds and cell states of acute myeloid leukemia (AML) influence the effectiveness of new therapies, particularly those combining azacitidine and venetoclax. This approach could help identify which patients are more likely to benefit from specific treatments based on their unique cellular characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who are considering treatment options.
Not a fit: Patients with other types of leukemia or those who are not eligible for the specific treatments being investigated may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for patients with acute myeloid leukemia.
How similar studies have performed: Previous research has shown promising results using similar approaches to assess treatment sensitivity in leukemia, indicating a potential for success in this study.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Cai, Sheng — Sloan-Kettering Inst Can Research
- Study coordinator: Cai, Sheng
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.